VIR BIOTECHNOLOGY INC's ticker is VIR and the CUSIP is 92764N102. A total of 144 filers reported holding VIR BIOTECHNOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $315 | -58.7% | 33,629 | +8.1% | 0.00% | -50.0% |
| Q2 2023 | $763 | +4.0% | 31,118 | -1.3% | 0.01% | 0.0% |
| Q1 2023 | $734 | -14.8% | 31,541 | -7.4% | 0.01% | -25.0% |
| Q4 2022 | $862 | -99.9% | 34,049 | +0.7% | 0.01% | +33.3% |
| Q3 2022 | $652,000 | -22.7% | 33,821 | +2.1% | 0.01% | -25.0% |
| Q2 2022 | $843,000 | +234.5% | 33,117 | +237.8% | 0.01% | +300.0% |
| Q1 2022 | $252,000 | -71.6% | 9,803 | -53.7% | 0.00% | -33.3% |
| Q4 2021 | $886,000 | +90.5% | 21,158 | +97.8% | 0.00% | -25.0% |
| Q3 2021 | $465,000 | -13.4% | 10,694 | -5.8% | 0.00% | 0.0% |
| Q2 2021 | $537,000 | +37.3% | 11,353 | +48.8% | 0.00% | -73.3% |
| Q1 2021 | $391,000 | +74.6% | 7,628 | -8.9% | 0.02% | +87.5% |
| Q4 2020 | $224,000 | -21.7% | 8,372 | +0.5% | 0.01% | -33.3% |
| Q3 2020 | $286,000 | -5.9% | 8,331 | +12.4% | 0.01% | -14.3% |
| Q2 2020 | $304,000 | – | 7,409 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 22,616,666 | $284,405,000 | 3.12% |
| INDUS CAPITAL PARTNERS, LLC | 681,936 | $8,575,000 | 1.68% |
| Alphabet Inc. | 1,666,666 | $20,958,000 | 1.27% |
| Temasek Holdings (Private) Ltd | 5,499,999 | $69,162,000 | 0.45% |
| Board of Trustees of The Leland Stanford Junior University | 38,905 | $490,000 | 0.06% |
| Baillie Gifford | 500,000 | $6,287,000 | 0.01% |
| Marshall Wace North America L.P. | 74,898 | $941,000 | 0.01% |
| Capital International Investors | 983,300 | $12,365,000 | 0.00% |
| Blackstone Inc. | 35,000 | $440,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,908 | $24,000 | 0.00% |